The Bio Report

A weekly Business podcast
Good podcast? Give it some love!

Episodes of The Bio Report

One of the consequences of the proliferation of genetic sequencing has been a shortage of genetic counselors. It’s left existing counselors to manage a heavy load as its increased the demands on onboarding patients, consenting them, educating t
While CAR-T cell therapies have emerged as promising anti-cancer agents, their success have been focused on hematologic cancers. ArsenalBio is working to develop more robust cell therapies capable to treating a broader range of cancers by using
Liquid biopsies have become associated with the area of oncology as they hold the promise of using fragments of DNA circulating in the blood that have been shed by tumors to provide early indications of recurrence and customize treatment strate
The World Health Organization estimates that 270 million people worldwide suffer from chronic hepatitis B virus infections, making it a global epidemic that affects more than twice the number of people with hepatitis C and HIV combined. HBV is
Psychedelics have become an area of increasing investment and drug development activities as an emerging group of companies is working to develop these compounds as treatments for neurologic and psychiatric conditions. That’s because of the abi
Type 2 diabetes affects nearly 500 million people worldwide and more than 34 million people in the United States. The disease carries an elevated risks of heart attack, stroke, and other serious complications. Fractyl Health believes the approa
The efforts to develop drugs for neurologic and psychiatric conditions has been plagued with failure. Herophilus is combining organoids derived from patient stem cells along with machine learning to gain new insight into the biology underlying
While the class of immunotherapies known as checkpoint inhibitors has brought a promising new approach to treating cancer, the development of resistance to these therapies limits the number of patients they benefit. Portage Biotech is building
Earth will not live forever. Whether its destruction comes as the result of cosmic inevitability or human-caused cataclysm, the planet will eventually meet its demise. Though that may be billions of years from now, Chris Mason in his book “The
While great strides have been made the fight against cancer with new therapies, dose-limiting toxicities of these agents can have a big impact on the quality of life for patients and lead doctors to alter dosing at the price of optimal outcomes
While great progress has been made in understanding the human genome, its functional counterpart, the human proteome, remains relatively unexplored. In part, that’s because advances in the tools to identify the far bigger universe of protein va
The development of mRNA therapies is allowing drug developer to pursue targets once considered undruggable. Anima Biotech has developed a platform that allows it to use small molecule that selectively control mRNA and can decrease or increase t
The biopharmaceutical industry has long struggled with R&D productivity. Long time industry strategic consultant Mike Rea, founder and CEO IDEA Pharma, thinks he’s hit on a possible solution. Taking a cue from the tech industry, Rea in May anno
While cities across the country have lifted COVID-19 restrictions and public gatherings have returned, the lack of effective treatments for people who develop severe reactions to the virus continues to pose a public health problem. The situatio
Osteoarthritis is a painful, progressive disease of the joints for which there is no cure. The condition affects more than 32.5 million adults in the United State and the incidence is growing as a result of aging, obesity, and sports injuries.
Sumitomo Dainippon Pharma’s $3 billion strategic transaction with Roivant Sciences that gave rise to Sumitovant, represents an effort by the Japanese drug company to make the drug development process faster and more efficient. A critical piece
The ability to identify diseases at their earliest stages through the detection of minute levels of biomarkers offers the potential to make interventions before the outward physical manifestations of illnesses can bloom and long-term damage can
The marriage of synthetic biology to mRNA is creating the potential for a range of programmable therapeutics that can provide new ways of treating deadly and chronic diseases. Strand Therapeutics is creating a platform for developing these long
Cardiometabolic conditions, such as type 2 diabetes and heart disease, have long been treated with pharmacologic interventions. Better Therapeutics believes cognitive behavioral therapy delivered through its prescription digital therapeutics pl
The side effects of opioids and the potential for addiction underlies the need for new approaches to the treatment of pain. SiteOne therapeutics is developing a pipeline of therapies that target sodium ion channels to block the electric signals
Earlier this year NovelluxDx rebranded itself as Fore Biotherapeutics signaling a shift from being a diagnostics company to its new life as a precision cancer therapeutics drug developer. Building on its functional genomics platform, the compan
When variants of the COVID-19 virus emerged in late 2020, it raised concerns about whether people already infected with the original virus, or vaccinated against it, would be able to generate a protective immune response that would confer prote
Hypoxia, a potentially fatal shortage of oxygen in tissues, is a complicating factor in a variety of serious illnesses including cancer, cardiovascular disease, and respiratory conditions. Diffusion Pharmaceuticals lead experimental candidate,
Wet age-related macular degeneration is a progressive disease and a leading cause of vision loss in patients over the age of 60. Vision loss is caused by the leakage of blood and other fluid from abnormal blood vessel growth underneath and into
TNF inhibitors, such as Humira and Remicade, have been a great biotech success story. These multi-billion franchises treat a range of autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn’s disease. Jim Woody, who led Cento
Rate Podcast
Do you host or manage this podcast?
Claim and edit this page to your liking.
Are we missing an episode or update?
Use this to check the RSS feed immediately.